Novavax (NVAX) ended the recent trading session at ... Meanwhile, the Dow experienced a rise of 1.65%, and the technology-dominated Nasdaq saw an increase of 2.45%. Coming into today, shares ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) crossed above their 200 day moving average of $10.66, changing hands as high as $11.55 per share. Novavax, Inc. shares are currently ...

$100,000 of NOVAVAX INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...

Investors in Novavax, Inc. (Symbol: NVAX) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX ...

Shares of Novavax (NVAX) have gained 3.5% over the past four weeks to close the last trading session at $8.81, but there could still be a solid upside left in the stock if short-term price targets ...

Below is a chart showing PPTA's trailing twelve month trading history, with the $12.50 strike highlighted in orange: And Novavax, Inc. (Symbol: NVAX) saw options trading volume of 30,747 contracts ...

Novavax NVAX shares soared 10.9% in the last trading session to close at $10.82. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Three of VBK's underlying holdings with notable upside to their analyst target prices are Evolent Health Inc (Symbol: EVH), MediaAlpha Inc (Symbol: MAX), and Novavax, Inc. (Symbol: NVAX).

CureVac is developing this investigational mRNA-based vaccine in collaboration with GSK. Novavax NVAX is also developing a bird flu vaccine in preclinical studies. NVAX claimed that this vaccine ...

Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have been given a consensus recommendation of “Hold” by the six ratings firms that are covering the firm, Marketbeat reports.

Novavax, Inc. (NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated ...